Medication info
JanuaTin Duo Tablet 50/850 mg

JanuaTin Duo Tablet 50/850 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
FarmGen Science Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300843 · Approved 2023.03.13 · Insurance code 670105450

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin treatment: For patients with no prior experience of antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily; the dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin treatment: - The recommended initial dose of this medicine for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg), together with the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral blood glucose-lowering agents to this medicine. Any change in the treatment regimen for type 2 diabetes may lead to changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
FarmGen Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes. It is primarily administered as an adjunct to dietary control and exercise therapy and is a combination medication of sitagliptin and metformin. This helps to manage blood sugar effectively and contributes to the prevention of complications. When taken according to the patient's health condition, it can be very helpful in improving blood sugar control.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin treatment: For patients with no prior experience of antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily; the dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin treatment: - The recommended initial dose of this medicine for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg), together with the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral blood glucose-lowering agents to this medicine. Any change in the treatment regimen for type 2 diabetes may lead to changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication contains sitagliptin and metformin, both of which are diabetes treatments. First, during the use of this medication, severe allergic reactions may occur, so if symptoms such as skin rash, hives, or difficulty breathing arise, discontinue use immediately and consult a physician. Acute pancreatitis has also been reported as a symptom of inflammation of the pancreas, so if sudden abdominal pain, nausea, or vomiting occur, visit the hospital immediately. This medication should not be used in patients with significantly reduced kidney function or in conditions affecting kidney function, such as severe infection, dehydration, or acute myocardial infarction. Particularly, use of this medication should be discontinued before and after examinations involving radiologic iodine contrast agents, and it may only be resumed after confirming normal kidney function post-examination. It is safer to avoid this medication for women who are pregnant, may become pregnant, or are breastfeeding. This medication may increase the risk of hypoglycemia or lactic acidosis when combined with irregular meals, vigorous exercise, or certain other medications, so caution is advised. Lactic acidosis is a rare but very serious side effect. If symptoms like weakness, muscle pain, difficulty breathing, abdominal pain, or altered consciousness occur, notify medical personnel immediately. During treatment, regular kidney function and blood tests should be conducted, and tests for vitamin B12 deficiency may also be necessary. Alcohol should be avoided during treatment, particularly excessive alcohol intake increases the risk of lactic acidosis. If symptoms of hypoglycemia appear, consume simple sugars immediately. If taking other hypoglycemic agents, dosage adjustment may be required to reduce the risk of hypoglycemia. In cases of surgery, discontinue the medication 48 hours prior to the procedure, and resume only after confirming normal kidney function post-operation. Finally, this medication is not recommended for use in children, especially under the age of 18, as safety and efficacy have not been established. If any unusual symptoms arise during treatment, it is essential to consult medical personnel immediately.

Side effects

  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 23 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe joint pain with disability
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • reduced appetite
  • gastrointestinal disturbances
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is recommended to maintain a storage temperature between 1 degree Celsius and 30 degrees Celsius at room temperature. This helps to prolong the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.